Tests bariatric surgery with GLP-1 medicines for severe obesity
Tests weight-loss surgery plus GLP-1 medicines in adults with severe obesity.
Plain-language title generated from the registry record
Registry title: Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07336862, who can take part
Where in China
- China-Japan Friendship HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT07336862
- Record updated
- 23 April 2026
- Original description
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.Read full original descriptionShow less
The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
Inclusion: Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG); obesity:BMI ≥35 kg/m²; Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria; Age range: 18-60 years (inclusive); Informed consent: Willing participation with documented consent.
Exclusion: Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively; Prior bariatric surgery: History of any metabolic/bariatric surgical procedure; Non-indicated candidates: Patients not meeting standard bariatric surgery indications; Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak); Significant comorbidities:; Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m²); Active malignancy (except non-melanoma skin cancers); Autoimmune disorders requiring immunosuppression; Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).